Arbutus Biopharma (ABUS) vs Kura Oncology (KURA)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.
Summary
Arbutus Biopharma (ABUS) has outperformed Kura Oncology (KURA) over the past year, losing 6.7% versus a loss of 38.1%. Over five years, ABUS leads with a +28.4% price change compared with -50.7% for KURA. Kura Oncology is the larger company by market cap ($634.9 million vs $616.2 million), about 1.0 times the size, while Arbutus Biopharma is growing revenue faster (+128.2% vs +25.2%).
Arbutus Biopharma converts more of its revenue into profit, with a net margin of -237.9% versus -412.9%.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | ABUS | KURA |
|---|---|---|
| Share price | $4.02 | $6.91 |
| Market cap | $616.24M | $634.88M |
| 1-day change | -1.23% | -5.99% |
| YTD return | -16.42% | -33.49% |
| 1-year return | -6.73% | -38.14% |
| 5-year return | +28.43% | -50.66% |
| P/E ratio (TTM) | 3.59 | — |
| EPS (TTM) | $1.12 | $-3.30 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | $14.08M | $67.48M |
| Revenue growth (YoY) | +128.21% | +25.24% |
| Net income (latest FY) | $-33.50M | $-278.67M |
| Operating margin | -270.96% | -449.94% |
| Net margin | -237.88% | -412.95% |
| 52-week high | $5.45 | $13.90 |
| 52-week low | $3.50 | $6.75 |
| Distance from 52-week high | -26.24% | -50.29% |
| Analyst consensus | none | strong_buy |
| Avg. price target upside | +32.34% | +357.60% |
| Average volume | 4.98M | 2.10M |
| Shares outstanding | 153.29M | 91.88M |
| Employees | 19 | 260 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- ABUS has outperformed KURA by 31.4 percentage points over the past year.
- Arbutus Biopharma is more profitable, keeping -237.9 cents of every revenue dollar as net income versus -412.9 cents for Kura Oncology.
- Arbutus Biopharma grew revenue faster in its latest fiscal year (+128.21% vs +25.24%).
About Arbutus Biopharma
ABUS stock →Arbutus Biopharma Corporation, a clinical-stage biopharmaceutical company, develops novel therapeutics for infectious disease in the United States. Its chronic Hepatitis B virus product pipeline comprises Imdusiran, conjugated GalNAc, subcutaneously-delivered RNAi therapeutic product candidate which is in phase 2a clinical trials that suppresses all HBV antigens, including HBsAg expression; and AB-101, an oral PD-L1 inhibitor, which is in phase 1a/1b clinical trial that has the potential to reawaken patients' HBV-specific immune response by inhibiting PD-L1.
Health Care · Biotechnology: Pharmaceutical Preparations · 19 employees
About Kura Oncology
KURA stock →Kura Oncology, Inc., a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancer. The company's first commercial product, KOMZIFTI (ziftomenib), a potent, selective, reversible and oral small molecule menin inhibitor; Darlifarnib, a Phase 1 first-in-human FIT-001 trial which includes multiple cohorts to evaluate darlifarnib in combination with other targeted therapies in large solid tumor indications; and KO-7246, a next-generation menin inhibitor, for use in diabetes and cardiometabolic disorders and additional next-generation menin inhibitors for use in combination with other therapies in solid tumors.
Health Care · Biotechnology: Pharmaceutical Preparations · 260 employees
ABUS vs KURA FAQ
Which is bigger, Arbutus Biopharma or Kura Oncology?
Kura Oncology (KURA) is larger, with a market capitalization of $634.88M compared with $616.24M for Arbutus Biopharma (ABUS).
Which stock has performed better over the past year, ABUS or KURA?
ABUS returned -6.73% over the past 12 months, compared with -38.14% for KURA (price return, excluding dividends). Past performance does not predict future results.
Are Arbutus Biopharma and Kura Oncology in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.